{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T17:46:11Z","timestamp":1792259171856,"version":"4.4.0"},"reference-count":10,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Anxiety disorders, including panic disorder, agoraphobia, specific phobias, and generalized anxiety disorder, are among the most frequent psychiatric conditions in primary care. They often present with somatic symptoms such as dyspnea, palpitations, chest or gastrointestinal discomfort, sweating, or flushing. Adaptol\u00ae is a non-benzodiazepine anxiolytic with nootropic properties that modulates the limbic-reticular system, hypothalamic emotional centers, and multiple neurotransmitter systems. This study aimed to assess the association between Adaptol\u00ae use and changes in anxiety symptoms, including somatic manifestations, in routine practice. Methods: A noninterventional observational study was conducted in 100 adults diagnosed with anxiety disorders in primary care. All received Adaptol\u00ae 500 mg as prescribed. Patients had to have mild-to-moderate anxiety (5\u201314 points according GAD-7) to be enrolled. Exclusion criteria ruled out individuals with concomitant psychiatric or severe somatic conditions and those with use of other medications or any interventions that could affect the symptoms. Anxiety severity and somatic symptom burden were assessed at baseline and after treatment. Results: Adaptol\u00ae treatment was associated with reduction in anxiety and somatic complaints. Improvements were reported in palpitations, chest discomfort, gastrointestinal disturbances, and autonomic symptoms. Greater benefit was observed in male patients, though without significance testing, and in those with severe baseline anxiety, as demonstrated by correlation between GAD-7 scores at baseline and changes after the treatment (r = 0.5). No unexpected adverse events occurred. Conclusions: In this real-world study, Adaptol\u00ae showed anxiolytic efficacy and good tolerability, improving both psychological and somatic manifestations of anxiety disorders. These findings support its use in primary care, especially in severe cases of anxiety. Controlled trials are needed to support these results.<\/jats:p>","DOI":"10.3390\/jcm14227972","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T17:45:34Z","timestamp":1762796734000},"page":"7972","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of Adaptol\u00ae 500 mg Tablets in Patients with Anxiety and Somatic Symptoms of Anxiety Disorder: A Noninterventional Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1144-8586","authenticated-orcid":false,"given":"Maris","family":"Taube","sequence":"first","affiliation":[{"name":"Department of Psychosomatic Medicine and Psychotherapy, Riga Stradi\u0146\u0161 University, 1083 Riga, Latvia"},{"name":"National Center of Mental Health, 1005 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5709-5758","authenticated-orcid":false,"given":"Guna","family":"Dansone","sequence":"additional","affiliation":[{"name":"Medical and Clinical Research Department, JSC Olpha, 2114 Olaine, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5080-7572","authenticated-orcid":false,"given":"Yulia","family":"Troshina","sequence":"additional","affiliation":[{"name":"Medical and Clinical Research Department, JSC Olpha, 2114 Olaine, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.cnur.2019.07.002","article-title":"Anxiety Disorders in Primary Care Settings","volume":"54","author":"Love","year":"2019","journal-title":"Nurs. Clin. N. Am."},{"key":"ref_2","unstructured":"Boland, R., Verduin, M.L., and Ruiz, P. (2022). Kaplan & Sadock\u2019s Synopsis of Psychiatry, Walters Kluver."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association. [5th ed.].","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref_4","unstructured":"(2025, September 10). Z\u0101\u013cu Valsts A\u0123ent\u016bra (State Medical Agency), Available online: https:\/\/dati.zva.gov.lv\/zalu-registrs\/info\/03-0002."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.17116\/jnevro202412407198","article-title":"Izuchenie effektivnosti i vliyaniya na kachestvo zhizni patsientov s subklinicheskim i klinicheski vyrazhennym trevozhnym rasstroistvom mobil\u2019nogo prilozheniya v sochetanii s terapiei preparatom Adaptol [To study the effectiveness and impact on the quality of life of patients with subclinical and clinically pronounced anxiety disorder of a mobile application in combination with Adaptol therapy]","volume":"124","author":"Levin","year":"2024","journal-title":"S.S. Korsakov J. Neurol. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.36740\/WLek202307105","article-title":"Treatment Optimization in Management of Combined Pathology\u2014Arterial Hypertension and Post-COVID Syndrome in Elderly Patients","volume":"76","author":"Kazakov","year":"2023","journal-title":"Wiad. Lek."},{"key":"ref_7","unstructured":"World Health Organization (2025, September 23). The ICD-10 Classification, 2016 (Latvian Version, 5th ed.), Available online: https:\/\/ssk10.spkc.gov.lv\/ssk\/g_119."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Spitzer, R.L., Kroenke, K., Williams, J.B.W., and L\u00f6we, B. (2025, September 23). Generalized Anxiety Disorder Scale (GAD-7). 2006 (Ori\u0123in\u0101ls). Local adaptation by Vrub\u013cevska et.al (2022). Available online: https:\/\/www.rsu.lv\/en\/psychology-laboratory\/test-and-survey-registry.","DOI":"10.1037\/t02591-000"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jad.2020.01.032","article-title":"Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7)","volume":"265","author":"Toussaint","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1017\/S0033291723002660","article-title":"A revitalized biopsychosocial model: Core theory, research paradigms, and clinical implications","volume":"53","author":"Bolton","year":"2023","journal-title":"Psychol. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/7972\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T05:27:51Z","timestamp":1762925271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/7972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":10,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14227972"],"URL":"https:\/\/doi.org\/10.3390\/jcm14227972","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]}}}